CN101854919B - 用于治疗肿瘤疾病的组合物 - Google Patents

用于治疗肿瘤疾病的组合物 Download PDF

Info

Publication number
CN101854919B
CN101854919B CN2008801042752A CN200880104275A CN101854919B CN 101854919 B CN101854919 B CN 101854919B CN 2008801042752 A CN2008801042752 A CN 2008801042752A CN 200880104275 A CN200880104275 A CN 200880104275A CN 101854919 B CN101854919 B CN 101854919B
Authority
CN
China
Prior art keywords
docetaxel
taxane
pvp
paclitaxel
ritonavir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801042752A
Other languages
English (en)
Chinese (zh)
Other versions
CN101854919A (zh
Inventor
J·H·贝内恩
J·H·M·舍伦斯
J·默斯
B·努伊耶恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Netherlands Cancer Institute
SLOTERVAART PARTICIPATIES BV
Original Assignee
Netherlands Cancer Institute
SLOTERVAART PARTICIPATIES BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Cancer Institute, SLOTERVAART PARTICIPATIES BV filed Critical Netherlands Cancer Institute
Priority claimed from PCT/GB2008/002854 external-priority patent/WO2009027644A2/en
Publication of CN101854919A publication Critical patent/CN101854919A/zh
Application granted granted Critical
Publication of CN101854919B publication Critical patent/CN101854919B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801042752A 2007-08-24 2008-08-22 用于治疗肿瘤疾病的组合物 Active CN101854919B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95776407P 2007-08-24 2007-08-24
GB0716591.3 2007-08-24
US60/957,764 2007-08-24
GB0716591A GB0716591D0 (en) 2007-08-24 2007-08-24 Composition
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition

Publications (2)

Publication Number Publication Date
CN101854919A CN101854919A (zh) 2010-10-06
CN101854919B true CN101854919B (zh) 2012-02-15

Family

ID=38599259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801042752A Active CN101854919B (zh) 2007-08-24 2008-08-22 用于治疗肿瘤疾病的组合物

Country Status (5)

Country Link
JP (1) JP5404625B2 (cg-RX-API-DMAC7.html)
CN (1) CN101854919B (cg-RX-API-DMAC7.html)
ES (1) ES2535401T3 (cg-RX-API-DMAC7.html)
GB (1) GB0716591D0 (cg-RX-API-DMAC7.html)
RU (1) RU2488384C2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106420A (zh) * 2015-07-30 2015-12-02 马衍福 一种抗肿瘤疾病中药制剂

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2015152433A1 (en) 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN118948828A (zh) 2017-03-15 2024-11-15 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法
WO2019047812A1 (zh) 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
MX2021007480A (es) * 2018-12-21 2021-10-13 Modra Pharmaceuticals B V Tratamiento de combinación para tumores sólidos utilizando docetaxel y un inhibidor de cyp3a.
ES3026709T3 (en) * 2018-12-21 2025-06-12 Modra Pharmaceuticals B V Cancer treatment using docetaxel by controlling peak plasma levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078619A1 (en) * 2002-11-13 2006-04-13 Hanmi Pharm Co., Ltd. Method for the preparatin of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371836C (en) * 1999-05-27 2006-01-31 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1539111A1 (en) * 2002-08-05 2005-06-15 DSM IP Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078619A1 (en) * 2002-11-13 2006-04-13 Hanmi Pharm Co., Ltd. Method for the preparatin of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106420A (zh) * 2015-07-30 2015-12-02 马衍福 一种抗肿瘤疾病中药制剂

Also Published As

Publication number Publication date
GB0716591D0 (en) 2007-10-03
JP5404625B2 (ja) 2014-02-05
JP2010536837A (ja) 2010-12-02
CN101854919A (zh) 2010-10-06
RU2010110658A (ru) 2011-09-27
ES2535401T3 (es) 2015-05-11
RU2488384C2 (ru) 2013-07-27
BRPI0816144A2 (pt) 2015-02-18

Similar Documents

Publication Publication Date Title
EP2190413B1 (en) Compositions for the treatment of neoplastic diseases
Peltier et al. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules
CN101854919B (zh) 用于治疗肿瘤疾病的组合物
Strickley Solubilizing excipients in oral and injectable formulations
Kalepu et al. Insoluble drug delivery strategies: review of recent advances and business prospects
Jibodh et al. Taxanes: old drugs, new oral formulations
US11471422B2 (en) Stealth, targeted nanoparticles (STN) for oral drug delivery
US20150231069A1 (en) Oral formulations of chemotherapeutic agents
JP2011042670A (ja) ナノ粒子のメロキシカム製剤
Thakkar Influence of excipients on drug absorption via modulation of intestinal transporters activity
KR20100057007A (ko) 치료제의 마이셀 캡슐화
CN111356445B (zh) 包含培美曲塞的口服用药学组合物及其制备方法
Murakami et al. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs
US20150328180A1 (en) Composition
CN104814971A (zh) 提高药物口服生物利用度的方法和低毒性乳清酸盐组合物
US20040198646A1 (en) Menthol solutions of drugs
HK1144390B (en) Compositions for the treatment of neoplastic diseases
BRPI0816144B1 (pt) Composição farmacêutica sólida para administração oral, uso da mesma e método para a preparação da dita composição
Watts et al. Recent developments in drug delivery to prolong allograft survival in lung transplant patients
Shah et al. International Journal of PharmaO2
Ahmad et al. Oral Administration of Cancer Chemotherapeutics Exploiting Self-Nanoemulsifying Drug Delivery System: Recent Progress and Application
US20060141028A1 (en) Cyclosporin formulations
Bansal PEGylated methotrexate based micellar conjugates for anticancer chemotherapy
Malingré Oral administration of taxanes
Ruiz-Gaton Pegylated nanoparticles to facilitate the intravenous-to-oral switch in docetaxel cancer chemotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant